Abstract
Based on a case study of a clinical stem cell intervention (CSCI) center in Chennai, India, this article explores distinct entrepreneurial strategies for the promotion of unrecognized clinical stem cell applications in India. It shows that the center—an Indo-Japanese joint-venture—is able to promote the CSCI due to its central position in a network relationship, its possession of specialized skills and knowledge, and its ability to maneuver other actors in the network and to identify and utilize their latent value. We examine the developmental history of the making and remaking of regulation and the shift in the way clinical stem cell application providers function—from institutional embedment to strategic linking through collaborative networks. We ask why and how unauthorized clinical applications are sustained and promoted in India. We conclude that this is possible as a result of a number of factors: jurisdictional ambiguity, institutional inability, issues concerning the legal enforceability of the relevant guidelines, the complexity of the collaborative network structure that facilitates the circumvention of the regulation, and the nonfunctioning of apex-level committees.
Acknowledgments
We are grateful for comments on the manuscript by the anonymous reviewers. This article has benefited from research support provided by the European Research Council (283219) and the Economic and Social Research Council (ESRC). Due to ethical concerns, supporting data cannot be made openly available.
Notes
1 DBT home page, dbtindia.nic.in/index.asp (accessed 24 August 2014).
2 IJRM (pseudonym) web page (accessed 24 August 2014). Address withheld. All material from the IJRM website in the text was accessed on this date.
Additional information
Notes on contributors
Margaret Sleeboom-Faulkner
Prasanna Kumar Patra is reader in anthropology at Utkal University (Bhbubaneswar, India). His work particularly examines the complexities in proliferation, translational bionetworking, and collaborations of stem cell research and therapy in India, comparing what is happening in other Asian countries, such as Japan.
Margaret Sleeboom-Faulkner is professor of social and medical anthropology at the University of Sussex. Her work focuses on processes of nation-state building in China and Japan and on biotechnology and society in Asia. Her latest research projects concern international life science networks in the fields of biobanking and biomaterials, as well as stem cell therapies and experimentality (funded by the European Research Council and the Economic and Social Science Research Council, respectively, 2011–17).